Drug intelligence / Profile preview

AS4040605

Development stage: Unknown
Lead developer: Astellas Pharma

Overview

AS4040605: sourced facts only. name: "We discovered a novel compound, AS4040605, that inhibits the activity of mouse and human ILC2s and identified that its target is Retinoic acid receptor-α (RARα)." [PMID:40288557]; target: "We discovered a novel compound, AS4040605, that inhibits the activity of mouse and human ILC2s and identified that its target is Retinoic acid receptor-α (RARα)." [PMID:40288557]; developer: "Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan. Electronic address: [email protected]." [PMID:40288557]

Beyond the preview

Go deeper on AS4040605.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AS4040605.